other material
confidence high
sentiment positive
materiality 0.65
Telomir-1 reduces tumor size ~50% in prostate cancer model; protects against chemo toxicity
Telomir Pharmaceuticals, Inc.
- Telomir-1 alone (low and high doses) reduced tumor growth ~50% in aggressive human prostate cancer animal model.
- Contrary to concerns, Telomir-1 suppressed tumor development and selectively benefited healthy cells.
- Paclitaxel alone caused severe toxicity with one-third mortality; adding low-dose Telomir-1 eliminated mortality.
- Telomir-1 combined with Paclitaxel neutralized chemotherapy-induced toxicity and weight loss.
- Results position Telomir-1 as a potential adjunct to standard chemotherapy for prostate cancer.